nach oben

Drugs in R&D

Erschienen in:

01.01.2003 | Adis R&D Profile

Sitafloxacin

DU 6859, DU 6859A, Gracevit™, Sitafloxacin Hydrate

Erschienen in: Drugs in R&D | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Excerpt

Sitafloxacin [DU 6859, DU 6859A, sitafloxacin hydrate, Gracevit™] is a novel N1-fluorocyclopropyl quinolone with very potent bactericidal activity against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and Bacteroides spp.¹ The compound is characterised by a cis-oriented (1R,2S)-2-fluorocyclopropylamine moiety that is indispensable for its reduced side effects and superior pharmacokinetic profile. …

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Aoki H, Tachibana M, Tanaka M, et al. DU-6859a, a novel quinolone: identification of the main metabolite in rats. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 302, 1993

Nakashima M, Uematsu T, Nakano M, Kosuge K, Tanaka M, et al. Pharmacokinetics and safety investigation of a new fluoroquinolone, DU-6859a in healthy male volunteers. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 303, 1993

Spencer L, Oliver S. DU-6859 (sitafloxacin)-absolute bioavailability study in healthy male and female subjects. Clinical Pharmacology and Therapeutics. 69: P48, Feb 2001CrossRef

Nozaki M, Kohno K, Tsurumi K. No convulsion was observed in mice: concomitant use of DU-6859a and non-steroidal antiinflammatory drugs. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 303, 1993

Kobayashi H. The clinical efficacy of sitafloxacin (DU-6859a) in respiratory tract infection. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 130 (plus poster), Jul 1999

Matsuda S. Clinical efficacy and tissue penetration of sitafloxacin (DI-6859a) in obstetrical and gynaecological infections. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 144 (plus poster), Jul 1999. Koto Hospital, Tokyo, Japan

Sasaki J. Clinical efficacy of sitafloxacin (DU-6859a) against infectious diseases in dentistry and oral surgery, and its pharmacokinetics. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 140–141 (plus poster), Jul 1999

Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy. 42: 1751–1755, Jul 1998PubMed

Ishida Y, Otani T, Ohashi M, Someya K, Yoshida K, et al. DU- 6859a, a new quinolone: therapeutic efficacy on experimental pneumonia due to Pseudomonas aeruginosa and Streptococcus pneumoniae. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 302, 1993

10.

Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrobial Agents and Chemotherapy. 38: 2877–2882, Dec 1994PubMedCrossRef

11.

Mikamo H, Kawazoe K, Sato Y, Izumi K, Tamaya T. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. Journal of Antimicrobial Chemotherapy 41: 131–133, Jan 1998PubMedCrossRef

12.

Miyashita N, Niki Y, Matsushima T. In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrobial Agents and Chemotherapy 45: 3270–3272, Nov 2001PubMedCrossRef

13.

Inagaki Y, Yamamoto N, Chida T, Okamura N, Tanaka M. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers. Japanese Journal of Antibiotics 48: 368–379, Mar 1995PubMed

14.

Marshall SA, Jones RN, Murray PR, Washington JA, Allen SD, et al. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. Journal of Antimicrobial Chemotherapy 32: 877–884, Dec 1993PubMedCrossRef

15.

Tomayko JF, Korten V, Murray BE. DU-6859a, a new fluoroquinolone agent: comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli. Diagnostic Microbiology and Infectious Disease 20: 45–47, Sep 1994PubMedCrossRef

16.

Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrobial Agents and Chemotherapy 36: 1491–1498, Jul 1992PubMedCrossRef

17.

Felmingham D, Robbins MJ, Ghosh G, Bhogal H, Mehta M, et al. In vitro studies with DU-6859a — a new fluorochloroquinolone antimicrobial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 299, 1993

18.

Molitoris E, Wexler HM, Reeves D, Finegold SM. In vitro activity of DU 6859a against 330 strains of anaerobic bacteria. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 301, 1993

19.

Forstall GJ, Knapp CC, Washington JA. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Antimicrobial Agents and Chemotherapy 38: 1868–1870, Aug 1994PubMedCrossRef

20.

Kuwahara-Arai K, Hori S, Hiramatsu K. In vitro antimicrobial activity of a novel quinolone DU-6859a. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 298, 1993

21.

Pankuch GA, Jacobs MR, Appelbaum PC. Activity of DU- 6859A, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. 5th International Symposium on New Quinolones: 44, 1994

22.

Jones RN, Johnson DM, Biedenbach DJ, Marshall SA. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagnostic Microbiology and Infectious Disease 23: 123–127, Nov 1995PubMedCrossRef

23.

Deguchi T, Yasuda M, Nakano M, Kanematsu E, Ozeki S, et al. Antimicrobial activity of a new fluoroquinolone, DU- 6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. Journal of Antimicrobial Chemotherapy. 39: 247–249, Feb 1997PubMedCrossRef

24.

Goldstein EJC, Citron DM, Hunt Gerardo S, Hudspeth M, Vreni Merriam C. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrobial Agents and Chemotherapy 41: 1193–1195, May 1997PubMed

25.

Milatovic D, Fluit A, Schmitz F-J, Verhoef J. In vitro activity of sitafloxacin (DU-6859A) and six other fluoroquinolones. Part III: anaerobes. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 171 (plus poster), Jul 1999

26.

Ackermann G, Tang YJ, Rodloff AC, Silva Jr J, Cohen SH, et al. In vitro activity of sitafloxacin against Clostridium difficile. Journal of Antimicrobial Chemotherapy. 47: 722–724, May 2001PubMedCrossRef

27.

Giamarellos-Bourboulis EJ, Grecka P, Sambatakou H, et al. Comparative postantibiotic effect of sitafloxacin and trovafloxacin on methicillin-resistant Staphylococcus aureus. Drugs 58 (Suppl 2): 146–148, 1999CrossRef

28.

Kawada Y. Sitafloxacin (DU-6859a) in the treatment of genitourinary tract infections. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 142 (plus poster), Jul 1999

29.

Watanabe S, Arata J. Use of sitafloxacin (DU-6859a) in the treatment of skin infections and its skin penetration. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 146 (plus poster), Jul 1999

30.

Baba S. Clinical efficacy of sitafloxacin (DU-6859a) in otorhinolaryngological infections and its pharmacokinetics. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 146 (plus poster), Jul 1999

31.

Irimajiri S, Research Group for Infectious Enteric Diseases. Multi-center clinical trial of sitafloxacin (DU-6859a) in infectious enteritis. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 143 (plus poster), Jul 1999

32.

Ooishi M. Clinical efficacy and pharmacokinetics of sitafloxacin (DU-6859a) in the field of ophthalmology. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 144 (plus poster), Jul 1999

33.

Takifuji K, Tanimura H, Nagai Y, Iwakura S. Clinical effects of sitafloxacin (DU-6859a) on surgical infection and pharmacokinetic evaluation. Journal of Antimicrobial Chemotherapy. 44 (Suppl A): 146 (plus poster), Jul 1999

34.

Shetty N, Wilson APR. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 46: 633–637, Oct 2000PubMedCrossRef

Titel: Sitafloxacin
DU 6859, DU 6859A, Gracevit™, Sitafloxacin Hydrate
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 1/2003
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304010-00013

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Sitafloxacin

DU 6859, DU 6859A, Gracevit™, Sitafloxacin Hydrate

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Trabectedin

Talaporfin

Selegiline-Transdermal — Somerset

Immunosuppressive and Anti-Inflammatory Mechanisms of Triptolide, the Principal Active Diterpenoid from the Chinese Medicinal Herb Tripterygium wilfordii Hook. f.

Morphine/Dextromethorphan — Endo

MT 100